Trial Profile
A Phase I/II Clinical Trial of Omacetaxine, Azacitidine, and G-CSF for Relapsed and/or Refractory Myelodysplastic Syndromes
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 05 May 2017
Price :
$35
*
At a glance
- Drugs Omacetaxine mepesuccinate (Primary) ; Azacitidine; Azacitidine
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- 14 Dec 2016 Status changed from not yet recruiting to withdrawn prior to enrolment due to lack of funding to support clinical trial.
- 20 Jul 2016 New trial record